List of Excipients in Branded Drug PYRIDOXINE HYDROCHLORIDE

Generic Drugs Containing PYRIDOXINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Fresenius Kabi USA LLC	pyridoxine hydrochloride	63323-180	CHLOROBUTANOL
Fresenius Kabi USA LLC	pyridoxine hydrochloride	63323-180	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in PYRIDOXINE HYDROCHLORIDE?

# Of NDCs	Excipient
1	CHLOROBUTANOL
1	SODIUM HYDROXIDE

Pyridoxine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Pyridoxine hydrochloride is a mature, low-cost vitamin B6 active pharmaceutical ingredient with limited standalone patent protection. Commercial value is concentrated in formulation performance, dosage-form convenience, combination products, pediatric delivery, regulatory positioning, and supply reliability rather than in active-ingredient exclusivity. The strongest opportunities are oral solid-dose products, liquid and orally disintegrating formulations, prenatal and nutritional combinations, and differentiated products for patients who have difficulty swallowing.

What is the regulatory status of pyridoxine hydrochloride?

Pyridoxine hydrochloride is the hydrochloride salt of pyridoxine, a water-soluble vitamin B6 compound. It is used in prescription medicines, over-the-counter products, dietary supplements, nutritional products, and combination therapies.

Regulatory area	Commercial position
Active ingredient	Pyridoxine hydrochloride, vitamin B6
Prescription use	Treatment or prevention of pyridoxine deficiency and certain drug-induced or metabolic conditions
OTC and supplement use	Vitamin B6 supplementation and multivitamin products
Common dosage forms	Tablets, capsules, oral liquids, injections, chewables, orally disintegrating products
FDA pathway	NDA, ANDA, OTC monograph or dietary supplement framework, depending on product and claims
Patent profile	Mature active ingredient with limited standalone composition-of-matter protection
Primary differentiation	Formulation, delivery system, combination, quality, price, and channel access

FDA-approved pyridoxine injection products are used when oral administration is unsuitable or when rapid replacement is required. Product labeling identifies pyridoxine hydrochloride as the active ingredient and specifies excipient, storage, route, and concentration requirements (U.S. Food and Drug Administration, n.d.-a).

The regulatory pathway depends on the product’s intended use. A prescription product making disease-treatment claims generally requires an NDA or ANDA. A dietary supplement must comply with the Federal Food, Drug, and Cosmetic Act and the Dietary Supplement Health and Education Act, but cannot make unapproved disease claims (U.S. Food and Drug Administration, n.d.-b).

What excipient strategy is appropriate for pyridoxine hydrochloride tablets?

The optimal tablet formulation depends on dose, target market, release profile, manufacturing platform, and label positioning. Pyridoxine hydrochloride is generally compatible with conventional direct-compression and wet-granulation processes, but development must control blend uniformity, tablet robustness, moisture exposure, dissolution, and color stability.

Immediate-release tablet strategy

A conventional immediate-release tablet can use the following excipient architecture:

Functional role	Candidate excipients	Development objective
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Improve bulk, flow, and tablet weight
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improve granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Support rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improve powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduce tooling friction
Film coat	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide or permitted colorants	Improve handling, appearance, and light protection

Microcrystalline cellulose and crospovidone are practical choices for a low-dose tablet requiring rapid disintegration. Lactose can reduce cost but may be unsuitable for products targeting lactose-sensitive consumers or for certain formulation platforms. Mannitol supports a premium, sugar-free, mouthfeel-oriented product but increases formulation cost.

The tablet’s commercial positioning should determine excipient selection:

• A hospital generic should prioritize low cost, robust compression, and stable supply.
• A consumer supplement should prioritize clean-label, vegetarian, allergen-free, and sugar-free claims.
• A pediatric product should prioritize palatability, rapid dispersion, and low swallowing burden.
• A premium product may use mannitol, directly compressible excipients, natural colors, and a smaller tablet platform.

Low-dose content uniformity

Pyridoxine products often contain relatively small quantities of active ingredient compared with tablet mass. Content uniformity can therefore become a critical quality attribute. Direct blending may be adequate at higher loadings, but low-dose products may benefit from ordered mixing, geometric dilution, co-processing, or granulation.

Risk controls include:

1. Narrow particle-size distribution for pyridoxine hydrochloride.
2. Control of segregation during transfer and compression.
3. Validated blend sampling and content-uniformity methods.
4. Defined mixing energy and time.
5. Monitoring of bulk density and flowability.
6. Protection against electrostatic separation.

A high-dose vitamin B6 product may have fewer uniformity concerns, but the same controls remain important for combination products in which pyridoxine is one component among many.

Which excipients are best for orally disintegrating and chewable pyridoxine products?

Orally disintegrating and chewable products offer the clearest formulation-based differentiation in the consumer and pediatric markets.

Orally disintegrating tablets

A typical orally disintegrating platform may combine mannitol or a mannitol-based co-processed excipient with crospovidone, low-substituted hydroxypropyl cellulose, a sweetener, and a flavor system. The formulation should target:

• Short disintegration time.
• Low friability.
• Minimal grittiness.
• Acceptable mouthfeel.
• Adequate moisture resistance.
• Protection from excessive light exposure.

Pyridoxine hydrochloride has a bitter or acidic taste profile at certain concentrations. Taste masking may require flavoring, sweeteners, polymer coating, ion-exchange resin complexation, or a multiparticulate approach. The most economical approach for moderate-dose products is usually a sweetener-flavor system combined with a rapidly disintegrating base. Higher-dose or pediatric products may require stronger taste-masking technology.

Chewable tablets

Chewables can use mannitol, sorbitol, xylitol, maltitol, or directly compressible sugar systems. Key risks include hygroscopicity, tablet softening, capping, and microbial control in certain formulations.

Xylitol and sorbitol can improve mouthfeel but require moisture-management studies. Sugar-free positioning may support pharmacy, dental, pediatric, and wellness channels. The label must account for gastrointestinal tolerance where polyols are used at higher levels.

Powders and sachets

Pyridoxine hydrochloride is suitable for powders, stick packs, and sachets when the dose is combined with a flavoring base. These products can target consumers who have difficulty swallowing tablets. Formulation priorities are blend homogeneity, segregation control, moisture protection, and rapid dispersion.

How should liquid pyridoxine hydrochloride products be formulated?

Oral liquids create opportunities in pediatric, geriatric, hospital, and enteral-nutrition markets. They also introduce greater stability, microbial, and packaging risk than tablets.

A liquid formulation may include purified water, a buffer system, a sweetener, a viscosity modifier, a preservative when appropriate, a flavor, and a chelating or stabilizing system if supported by compatibility data. The formulation must be evaluated for:

• Chemical stability across the intended shelf life.
• pH-dependent degradation.
• Light sensitivity.
• Preservative effectiveness.
• Container-closure compatibility.
• Dose uniformity after storage.
• Sedimentation or crystallization.
• Palatability after dilution.

Potential excipient platforms include sucrose-based syrups, sorbitol or glycerin systems, and sugar-free suspensions. A clear solution is commercially attractive because it simplifies dosing and improves consumer acceptance, but a suspension may provide greater flexibility where solubility or taste masking is limiting.

Packaging is an important part of the product strategy. Amber bottles, unit-dose cups, oral syringes, and child-resistant closures can support different channels. A calibrated oral syringe is particularly valuable for pediatric products because household spoons produce inaccurate dosing.

Injectable products require a separate development strategy. Sterile water for injection, container-closure integrity, particulate control, endotoxin control, sterilization validation, and compatibility with the intended route are central requirements. The excipient system should remain minimal because parenteral products have a narrower tolerance for formulation complexity. FDA labeling and compendial requirements govern the finished product (U.S. Food and Drug Administration, n.d.-a; United States Pharmacopeia, 2024).

What patents protect pyridoxine hydrochloride products?

Standalone pyridoxine hydrochloride has a mature intellectual-property profile. The active ingredient itself is not a credible source of new composition-of-matter exclusivity for a conventional product.

IP category	Risk and opportunity
Active ingredient	Low opportunity for new standalone protection
Conventional tablet	Usually weak patent position unless tied to a specific formulation or manufacturing process
Oral liquid	Possible protection for stability, taste masking, delivery, or preservative systems
ODT and chewable	Possible formulation patents covering disintegration, taste masking, or excipient ratios
Combination product	Potential method-of-use, formulation, or combination patents
Manufacturing process	Potential protection for particle engineering, granulation, or impurity control
Packaging	Potential protection for light or moisture protection, usually narrow
Regulatory exclusivity	Product-specific; not generally a major driver for conventional pyridoxine products

The FDA Orange Book identifies approved drug products and, where applicable, listed patents and exclusivity information. A conventional standalone pyridoxine hydrochloride product generally does not have the Orange Book profile associated with a recently approved innovative drug (U.S. Food and Drug Administration, n.d.-c).

Patent risk can increase materially when pyridoxine is incorporated into a branded combination therapy. Doxylamine and pyridoxine delayed-release products used for nausea and vomiting of pregnancy have had product-specific patent and litigation activity. In that setting, the relevant IP may cover the combination, dosage regimen, delayed-release architecture, or method of use rather than pyridoxine hydrochloride alone.

When does pyridoxine hydrochloride lose exclusivity?

Pyridoxine hydrochloride has already passed the relevant patent-exclusivity period for conventional standalone products. Commercial entry is therefore governed mainly by regulatory approval, manufacturing cost, quality systems, supply contracts, and channel economics.

The exclusivity analysis differs by product type:

Product type	Main barrier to entry
Generic immediate-release tablet	ANDA approval, bioequivalence where required, CMC quality, price
Prescription oral liquid	Stability, microbial control, dosing accuracy, container compatibility
Injectable	Sterility, manufacturing capacity, inspection readiness, supply reliability
Dietary supplement	Ingredient compliance, labeling, quality, brand distribution
Combination product	Product-specific patents, formulation claims, method-of-use claims
Pediatric differentiated product	Taste, dose flexibility, clinical acceptability, packaging

Paragraph IV challenges are most relevant when an ANDA applicant contests patents listed for a branded combination product. They are less relevant to a basic standalone pyridoxine hydrochloride tablet without listed patents. A generic applicant must still assess formulation patents, method-of-use patents, regulatory exclusivity, and non-Orange Book patent assertions.

What commercial opportunities exist for pyridoxine hydrochloride?

Generic prescription products

A low-cost tablet or injectable can compete in hospital, institutional, and pharmacy channels. The principal commercial advantage is dependable supply. Injectable shortages, contract-manufacturing interruptions, or limited supplier qualification can create opportunities for a second-source manufacturer.

The strongest generic strategy is often not a novel excipient system. It is a validated, scalable process with:

• At least two qualified API sources where feasible.
• Consistent dissolution and content uniformity.
• Low defect rates.
• Reliable sterile manufacturing for injection.
• Competitive packaging and logistics.
• Multi-market regulatory filings.

Prenatal and pregnancy-related combinations

Pyridoxine is used in combination with doxylamine in prescription products for nausea and vomiting of pregnancy. This market has higher commercial value than a standalone vitamin tablet, but it also carries greater patent, regulatory, clinical, and pharmacovigilance complexity.

A company pursuing this segment must distinguish between:

1. A simple pyridoxine supplement, which cannot make prescription treatment claims.
2. A regulated combination drug, which requires the appropriate FDA pathway.
3. A generic version of an approved combination, which may face Orange Book patents and litigation.
4. A reformulated or alternative-release product, which may require new clinical and CMC support.

Pediatric and geriatric dosage forms

Small-volume oral liquids, chewables, ODTs, and unit-dose products can command higher margins than standard tablets. Differentiation is strongest where the product reduces swallowing difficulty or dosing error.

Commercially attractive features include:

• 1 mL or 5 mL dose flexibility.
• Oral-syringe compatibility.
• Sugar-free and alcohol-free formulations.
• Reduced tablet size.
• Improved taste.
• Light-protective packaging.
• Unit-dose hospital presentation.

Nutritional and wellness combinations

Pyridoxine is commonly included in multivitamins, B-complex products, prenatal products, and mineral combinations. The market is crowded, so differentiation must come from dosage form, consumer segment, quality certification, channel access, or clinically supportable positioning.

Potential segments include:

• Prenatal and postnatal nutrition.
• Vegan and vegetarian products.
• Senior multivitamins.
• Sports and active-lifestyle products.
• Hospital nutrition.
• Enteral and parenteral nutrition.
• Products designed for consumers who cannot swallow tablets.

Labeling must avoid disease claims unless the product is approved as a drug for those claims. Pyridoxine-related claims should remain within the applicable regulatory framework for supplements and foods (U.S. Food and Drug Administration, n.d.-b).

How strong is the patent estate for pyridoxine hydrochloride?

The standalone patent estate is weak for conventional products and stronger only where a company develops a technically specific platform.

Potentially protectable areas

• Taste-masked pyridoxine particles.
• Controlled- or delayed-release multiparticulates.
• Stable aqueous formulations.
• Low-dose content-uniformity processes.
• Novel excipient combinations that improve dissolution or shelf life.
• Pediatric delivery systems.
• Combination products with a defined clinical use.
• Manufacturing processes that reduce degradation products or improve purity.
• Light- and moisture-protective packaging integrated with product stability.

A formulation patent is more defensible when it links a defined composition to measurable performance, such as improved stability, dissolution, taste masking, bioavailability, or reduced degradation. Broad claims covering ordinary excipient combinations are vulnerable to obviousness challenges.

What manufacturing and IP barriers affect market entry?

The API is generally available from multiple suppliers, which reduces raw-material exclusivity but increases price competition. The principal manufacturing barriers are product-specific.

For tablets, the critical issues are blend uniformity, flow, compression, dissolution, and packaging. For liquids, stability and microbial control dominate. For injections, sterile manufacturing capacity, validated aseptic processes, container-closure integrity, and inspection history can determine whether a product is commercially viable.

Geographic opportunities vary:

Region	Primary opportunity
United States	Generic prescription products, supplements, prenatal combinations, pediatric products
European Union	Pharmacy generics, food supplements, pediatric liquids, combination products
Emerging markets	Low-cost tablets, injections, sachets, and public-sector supply
Asia-Pacific	API supply, contract manufacturing, supplements, export products
Hospital markets	Injectable and unit-dose products
E-commerce	Consumer supplements, gummies, chewables, and sachets

A manufacturer should avoid assuming that U.S. approval automatically supports claims or dosage formats in other markets. Vitamin classification, maximum permitted intake, labeling rules, excipient permissions, and registration requirements differ by jurisdiction.

How does pyridoxine hydrochloride compare with other vitamin B6 forms?

Form	Main advantage	Main limitation
Pyridoxine hydrochloride	Low cost, established supply, broad formulation familiarity	Limited product differentiation
Pyridoxal-5'-phosphate	Premium positioning and coenzyme-form marketing	Higher cost and greater stability/formulation complexity
Pyridoxine compounds in multivitamins	Broad consumer familiarity	Heavy price and brand competition

Pyridoxine hydrochloride is usually the preferred commercial form when cost, supply, and regulatory familiarity matter most. Pyridoxal-5'-phosphate may support premium supplement positioning, but the active-form narrative does not by itself establish a drug patent advantage.

What generic launch scenarios exist for pyridoxine products?

Scenario 1: Low-cost immediate-release tablet

This is the lowest-risk entry model. Success depends on manufacturing efficiency, API procurement, wholesale pricing, and supply continuity. Patent barriers are generally limited.

Scenario 2: Pediatric liquid or chewable

This model has greater formulation and stability risk but offers stronger differentiation and potentially higher margins. Taste masking, dosing accuracy, and packaging are decisive.

Scenario 3: Injectable second source

This can produce attractive institutional demand when supply is constrained. The development and quality burden is substantially higher than for oral products.

Scenario 4: Doxylamine-pyridoxine generic

This opportunity has higher revenue potential but requires a detailed review of listed patents, regulatory exclusivity, formulation release characteristics, and Paragraph IV litigation exposure.

Scenario 5: Premium supplement platform

A supplement can use clean-label excipients, vegan capsules, gummies, ODTs, or combination positioning. The market is commercially accessible but crowded and sensitive to advertising, quality, and customer-acquisition costs.

Key Takeaways

• Pyridoxine hydrochloride is a mature active ingredient with limited standalone patent value.
• Excipient strategy should be matched to the target channel: low-cost tablets for generics, robust liquids for pediatric use, and taste-masked ODTs or chewables for consumer differentiation.
• The most important formulation risks are content uniformity, moisture and light exposure, taste, liquid stability, and sterile manufacturing for injections.
• Standalone products generally have limited Orange Book and Paragraph IV exposure.
• Doxylamine-pyridoxine combinations require a separate patent and litigation analysis because product-specific formulation and method-of-use rights may apply.
• Commercial opportunities are strongest in pediatric delivery, hospital injectables, prenatal combinations, unit-dose products, and differentiated supplements.
• A defensible formulation patent should claim a specific composition linked to measurable performance.
• Manufacturing reliability, API sourcing, and regulatory execution are more important than active-ingredient exclusivity for conventional pyridoxine products.

FAQs About Pyridoxine Hydrochloride Formulation and Commercialization

Is pyridoxine hydrochloride suitable for direct compression?

Yes. Direct compression is feasible when particle size, flow, blend uniformity, and low-dose distribution are adequately controlled. Co-processed excipients may improve manufacturability.

Which excipients improve pyridoxine tablet disintegration?

Crospovidone, croscarmellose sodium, and sodium starch glycolate are common options. Selection should be based on dissolution, tablet strength, moisture sensitivity, and manufacturing process.

Can pyridoxine hydrochloride be used in a sugar-free pediatric liquid?

Yes. Sugar-free systems may use sorbitol, glycerin, or other suitable sweetening and viscosity platforms. Stability, preservative effectiveness, palatability, and dosing accuracy require product-specific validation.

Does pyridoxine hydrochloride have active composition-of-matter patent protection?

Conventional pyridoxine hydrochloride products generally do not rely on active-ingredient composition-of-matter exclusivity. Protection may arise from a specific formulation, combination, method of use, or manufacturing process.

Is pyridoxine hydrochloride a strong candidate for a 505(b)(2) product?

It can be, particularly for a differentiated delivery system, liquid, pediatric formulation, or combination product. The commercial case depends on clinical differentiation, regulatory requirements, formulation IP, and the target indication.

References

1. U.S. Food and Drug Administration. (n.d.-a). DailyMed: Pyridoxine hydrochloride injection labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.-b). Dietary supplements. https://www.fda.gov/food/dietary-supplements

3. U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary, USP 47-NF 42. U.S. Pharmacopeial Convention.